

Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045



April 13, 2023

Product Discontinuation Notification

Dear Valued Customer,

Pfizer Hospital is committed to providing supply information so that you can plan for patient care. The purpose of this letter is to make you aware of our intent to discontinue Bivalirudin for Injection 250 mg Single Dose ADD-Vantage® Glass Vial as well as the Single Dose Fliptop Vial, once inventory is exhausted. The decision to discontinue this product was made only after thorough assessment by Pfizer Hospital and is based on a combination of market need, manufacturing and portfolio considerations. The U.S. Food and Drug Administration (FDA) has been notified.

Below is the last lot shipped for each product with the expiration dates and estimated date for stock out.

NDC Number	Product Description	Unit of Sale Size	Ordering Status	Ordering/Shipping Method	Last Lot Shipped	Last Lot Exp Date	Estimated Stock Out Date
00409-8300-15	Bivalirudin for Injection 250 mg Single Dose ADD-Vantage® Glass Vial	10	Limited Supply	Wholesaler, Distributor & Direct Ship	39000CD	3/1/2024	Q1 2024
00409-8300-10	Bivalirudin for Injection 250 mg Single Dose Glass Fliptop Vial	10	Depleted	Wholesaler & Distributor	44030CD	8/2/2024	Stocked Out

For additional product availability questions, please reach out to your Pfizer Hospital sales representative or account executive. Alternatively, the Supply Continuity Team can be contacted between 7 a.m. and 6 p.m. (CT) at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]). For medical inquiries, please contact Pfizer Medical Information at 1-800-438-1985 or pfizermedinfo.com.

Thank you,

Jason Satterlee
Portfolio Director, Anti-Infectives & ADD-Vantage
Pfizer Hospital U.S.

Linna Wilkins
Portfolio Director, Cardiovascular & Steroids
Pfizer Hospital U.S.

